Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1444, 2004-01, pp. : 9-10
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
In erlotinib we TRUST to treat advanced NSCLC
Inpharma, Vol. 1, Iss. 1641, 2008-01 ,pp. :
Access to resources
Recommend
Bevacizumab combination improves survival in advanced NSCLC
Inpharma, Vol. 1, Iss. 1492, 2005-01 ,pp. :
Erlotinib dominates docetaxel for NSCLC
Inpharma, Vol. 1, Iss. 1612, 2007-01 ,pp. :
Erlotinib improves QOL in NSCLC
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 512, 2006-01 ,pp. :
Erlotinib dominates docetaxel for NSCLC
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 540, 2007-01 ,pp. :